China Resources Boya Bio pharmaceutical Group Co Ltd
SZSE:300294
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
China Resources Boya Bio pharmaceutical Group Co Ltd
China Resources Boya Bio pharmaceutical Group Co Ltd
Total Equity
China Resources Boya Bio pharmaceutical Group Co Ltd
Total Equity Peer Comparison
6160
1801
603392
300122
300896
Competitive Total Equity Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SZSE:300294
|
Total Equity
¥7.3B
|
CAGR 3-Years
20%
|
CAGR 5-Years
15%
|
CAGR 10-Years
25%
|
|
|
Beigene Ltd
HKEX:6160
|
Total Equity
¥25.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Total Equity
¥12.5B
|
CAGR 3-Years
13%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Total Equity
¥12.7B
|
CAGR 3-Years
71%
|
CAGR 5-Years
57%
|
CAGR 10-Years
N/A
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Total Equity
¥31.5B
|
CAGR 3-Years
51%
|
CAGR 5-Years
46%
|
CAGR 10-Years
29%
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Total Equity
¥5.8B
|
CAGR 3-Years
107%
|
CAGR 5-Years
78%
|
CAGR 10-Years
N/A
|
See Also
What is China Resources Boya Bio pharmaceutical Group Co Ltd's Total Equity?
Total Equity
7.3B
CNY
Based on the financial report for Mar 31, 2024, China Resources Boya Bio pharmaceutical Group Co Ltd's Total Equity amounts to 7.3B CNY.
What is China Resources Boya Bio pharmaceutical Group Co Ltd's Total Equity growth rate?
Total Equity CAGR 10Y
25%
Over the last year, the Total Equity growth was 0%. The average annual Total Equity growth rates for China Resources Boya Bio pharmaceutical Group Co Ltd have been 20% over the past three years , 15% over the past five years , and 25% over the past ten years .
You don't have any saved screeners yet
